Short Interest in Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) Rises By 16.5%

Concert Pharmaceuticals, Inc. (NASDAQ:CNCEGet Rating) saw a large growth in short interest in the month of July. As of July 15th, there was short interest totalling 1,100,000 shares, a growth of 16.5% from the June 30th total of 944,600 shares. Based on an average daily trading volume, of 818,800 shares, the days-to-cover ratio is currently 1.3 days.

Insider Buying and Selling at Concert Pharmaceuticals

In other news, Director Heek Christi Van bought 10,526 shares of the firm’s stock in a transaction dated Monday, June 6th. The stock was acquired at an average price of $4.75 per share, for a total transaction of $49,998.50. Following the acquisition, the director now owns 25,651 shares of the company’s stock, valued at $121,842.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 10.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Concert Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in CNCE. Roanoke Asset Management Corp NY acquired a new stake in shares of Concert Pharmaceuticals during the 1st quarter valued at approximately $34,000. Virtu Financial LLC bought a new position in Concert Pharmaceuticals during the 1st quarter worth $47,000. Jane Street Group LLC bought a new position in Concert Pharmaceuticals during the 1st quarter worth $56,000. Charles Schwab Investment Management Inc. bought a new position in Concert Pharmaceuticals during the 1st quarter worth $80,000. Finally, State Street Corp grew its stake in Concert Pharmaceuticals by 7.2% during the 1st quarter. State Street Corp now owns 75,798 shares of the biotechnology company’s stock worth $255,000 after buying an additional 5,058 shares during the last quarter. 51.26% of the stock is owned by institutional investors and hedge funds.

Concert Pharmaceuticals Stock Down 2.0 %

Shares of CNCE opened at $6.00 on Thursday. The business’s 50 day moving average is $4.83 and its two-hundred day moving average is $3.84. Concert Pharmaceuticals has a 52-week low of $2.57 and a 52-week high of $6.88. The firm has a market cap of $217.97 million, a price-to-earnings ratio of -2.26 and a beta of 0.69.

Concert Pharmaceuticals (NASDAQ:CNCEGet Rating) last posted its quarterly earnings results on Thursday, May 5th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.07). Concert Pharmaceuticals had a negative net margin of 245.72% and a negative return on equity of 89.48%. During the same period last year, the business earned ($0.67) EPS. On average, equities analysts expect that Concert Pharmaceuticals will post -3.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on Concert Pharmaceuticals in a research report on Wednesday, June 15th. They set a “hold” rating on the stock.

Concert Pharmaceuticals Company Profile

(Get Rating)

Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition.

Featured Articles

Receive News & Ratings for Concert Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.